Leap Therapeutics Inc - LPTX Net earnings per share for the last four quarters

Official company branding of Leap Tx (LPTX)

The annual EPS TTM YoY trend for Leap Therapeutics, Inc. (LPTX) demonstrates the resilience of its gastric cancer therapy patents, which create a defensive barrier. However, the high cost of rare tumor trials and FDA safety requirements remain significant risks. The -15.20 metric confirms the current level, while dependence on Asian supplies and logistics determines the overall stability of the business.

Leap Therapeutics (LPTX) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

LPTX (Leap Therapeutics Inc): analytical breakdowns and indicator data

Initial company analysis:LPTX, Leap Therapeutics, Inc.
Mass-produced product of Leap Therapeutics

The development of innovative immunotherapeutic treatments for gastrointestinal cancer places Leap Therapeutics, Inc. (LPTX) in the category of high-risk assets with potential for exponential growth. By analyzing the YoY ttm earnings per share growth chart, an investor assesses the net income dynamics over the year, which allows for a comparison of current business efficiency against market capitalization and determines the company's stage of fundamental development.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months